Chikungunya – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Chikungunya
is a zoonotic illness caused by the Chikungunya virus (CHIKV) and is spread
through the bites of infected Aedes aegypti, Aedes albopictus, and Aedes
polynesienses mosquitoes. This disease typically manifests with a sudden onset
of fever and severe joint pain. Additionally, individuals may experience
symptoms like headaches, muscle pain, fatigue, and a rash. The incubation
period varies from 1 to 12 days, with an average of 2 to 7 days. CHIKV
infection results in high viremia levels, usually persisting for 4 to 6 days
after symptoms emerge. Most people infected with CHIKV exhibit symptoms, while
less than 15% experience asymptomatic seroconversion. Various laboratory tests
are available to diagnose CHIK, utilizing serum or plasma samples to detect the
virus, viral nucleic acid, virus-specific immunoglobulin (Ig) IgM, and
neutralizing antibodies. Currently, there is no vaccine or specific medication
for treating Chikungunya. However, palliative treatments are available,
including Analgesics and non-steroidal anti-inflammatory drugs to alleviate
joint pain, Rest, hydration, over-the-counter pain relievers, Low-dose oral
prednisolone to manage persistent synovitis and tenosynovitis. Serious
complications associated with Chikungunya encompass myocarditis, uveitis,
retinitis, hepatitis, acute renal disease, severe bullous lesions,
meningoencephalitis, Guillain-Barré syndrome, myelitis, and cranial nerve
palsies.
Thelansis’s
“Chikungunya Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2023 To 2033" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Chikungunya treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights of Chikungunya across 8
MM market from the centre of Excellence/ Public/ Private hospitals participated
in the study. Insights around current treatment landscape, epidemiology,
clinical characteristics, future treatment paradigm, and Unmet needs.
Chikungunya
Market Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Chikungunya,
Chikungunya market outlook, Chikungunya competitive landscape, Chikungunya market forecast, Thelansis, Primary market research, KOL
insights, Competitive Intelligence (CI)
Comments
Post a Comment